My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Pfizer (NY:PFE)

25.85 +0.05 (+0.19%)

Official Closing Price Updated: 7:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Market Reels from Volatility and Mixed Signals: A Deep Dive into Investor Unease

November 08, 2025

The past week, from November 1st to November 8th, 2025, has witnessed a significant shift in global market sentiment, moving decisively towards a "risk-off" stance. Investors are grappling with...

Via MarketMinute

2 No-Brainer Dividend Stocks to Buy With $100 in November ↗

November 08, 2025

There's no need to break the bank to get your hands on excellent dividend payers.

Via The Motley Fool

Topics Economy World Trade

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors. ↗

November 08, 2025

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.

Via The Motley Fool

Topics Government

Global Virtual Summit Puts the Spotlight on Sickle Cell Caregivers

November 08, 2025

November 8, 2025 -- Four-Day Event Unites Families, Advocates, and Medical Experts to Prioritize Mental Wellness, Advocacy, and Legacy

Via 24-7 Press Release

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗

November 08, 2025

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."

Via Benzinga

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy ↗

November 07, 2025

Via Benzinga

Why Novo Nordisk Stock Is Sinking This Week ↗

November 07, 2025

The global drugmaker is facing some headwinds related to tough competition.

Via The Motley Fool

Topics Government World Trade

The Stock Market Is Signaling a Recession. Here's How to Prepare Your Portfolio.

November 07, 2025

The financial markets are increasingly flashing warning signs that an economic recession may be on the horizon, prompting investors to re-evaluate their strategies. A confluence of indicators, from...

Via MarketMinute

Topics Bonds Economy Stocks

Friday's session: most active stock in the S&P500 index ↗

November 07, 2025

Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements.

Via Chartmill

Tech Sell-Off Rocks Wall Street: Nasdaq, S&P 500, and Dow Sink Amidst Brutal Week for Stocks

November 07, 2025

New York, NY – November 7, 2025 – The U.S. stock market has been gripped by a significant downturn in early November 2025, culminating in a brutal week that saw the Nasdaq Composite, S&P 500, and Dow...

Via MarketMinute

Topics Artificial Intelligence Economy Retirement

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Sangamo (SGMO) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Sangamo (SGMO) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

US Stocks Tumble Amid AI Valuation Fears and Mounting Job Worries

November 06, 2025

The U.S. stock market experienced a notable downturn today, November 6, 2025, as investors grappled with growing apprehension over the lofty valuations of artificial intelligence (AI) stocks and a...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Famed Investor Michael Burry Bets Against Nvidia and Palantir to the Tune of $1.1 billion. Is He Right? ↗

November 06, 2025

Burry is famous for shorting the market during the mortgage crisis. Is he going to win big again?

Via The Motley Fool

Topics Artificial Intelligence

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗

November 06, 2025

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.

Via Benzinga

Topics Government

Stay informed about the most active stocks in the S&P500 index on Thursday's session. ↗

November 06, 2025

Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest...

Via Chartmill

3 Value Stocks That Fall Short

November 06, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal ↗

November 06, 2025

Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer.

Via Benzinga

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further ↗

November 06, 2025

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through.

Via Stocktwits

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera ↗

November 06, 2025

Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.

Via Investor's Business Daily

Market Momentum Stalls: Valuations Under Scrutiny as Bullish Run Faces Headwinds

November 06, 2025

As November 2025 unfolds, the global stock markets find themselves at a critical juncture, struggling to reclaim the robust bullish momentum that characterized much of the preceding years. A palpable...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Viatris’s (NASDAQ:VTRS) Q3 Sales Top Estimates

November 06, 2025

Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1...

Via StockStory

Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting ↗

November 06, 2025

Pfizer just gave income investors four reasons to like its juicy dividend even more.

Via The Motley Fool

Topics Earnings Intellectual Property

2 Dirt Cheap Stocks to Buy With $1,000 Right Now ↗

November 06, 2025

With big yields, these turnaround stocks look like they are attractively priced for those who can handle some uncertainty.

Via The Motley Fool

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal ↗

November 05, 2025

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

Via Stocktwits

Topics Law Enforcement

US Economic Resilience Fuels Dollar's Ascent Amidst Global Shifts

November 05, 2025

The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Pfizer Responds to Delaware Chancery Court Ruling

November 05, 2025

From Pfizer Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.